ALUMIS INC.
About ALUMIS INC.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $24.1M
- Net income
- -$243.3M
- Total assets
- $411.9M
- Market cap
- $2.4B
- Operating margin
- -1886.9%
- Net margin
- -1011.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $24.1M
- Operating expenses
- $477.9M
- Operating income
- -$453.8M
- Income tax
- -$8.6M
- Net income
- -$243.3M
- EPS (basic)
- $-2.86
- EPS (diluted)
- $-2.86
Balance sheet
- Total assets
- $411.9M
- Current assets
- $318.2M
- Total liabilities
- $110.6M
- Current liabilities
- $73.3M
- Shareholders’ equity
- $301.3M
Cash flow
- Operating cash flow
- -$369.5M
- Investing cash flow
- $287.9M
- Financing cash flow
- $2.1M
- Net cash flow
- -$79.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.4B
- EPS (diluted)
- $-2.86
- Shares outstanding
- 128.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 28, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $243.3M in FY2025.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ALUMIS INC..
Write a review
News about ALUMIS INC.
News & sentiment via Polygon.io
